TGA commences evaluation of Moderna COVID 19 vaccine (SPIKEVAX) for children aged 6 months to 5 years old
The TGA has received and commenced evaluation of an application to extend the use of its COVID-19 vaccine, SPIKEVAX, to children aged 6 months to 5 years old.
Published
Related content
-
TGA grants provisional determination for the Moderna COVID-19 vaccine, Elasomeran
The TGA, part of the Department of Health, has granted provisional determination to Moderna Australia Pty Ltd in relation to the COVID-19 Vaccine, Elasomeran -
TGA commences evaluation of Moderna COVID-19 vaccine (SPIKEVAX) for potential transition to full registration
The TGA has commenced evaluation of an application from Moderna Australia Pty Ltd to transition its COVID-19 vaccine, SPIKEVAX, to full registration for the immunisation of individuals 6 years and over, and as a booster dose for individuals aged 12 years and older. -
TGA provisionally approves Moderna's COVID-19 vaccine
On 9 August 2021 the TGA granted provisional approval to Moderna Australia Pty Ltd in relation to the COVID-19 vaccine, Spikevax (elasomeran), for individuals aged 18 years and over.